Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | STI-1492 |
Synonyms | |
Therapy Description |
STI-1492 are allogeneic T-cells engineered to knockout TCR alpha and express a dimeric antigen receptor targeting CD38 and containing 4-1BB and CD3-zeta signaling domains, which potentially induce toxicity against tumor cells expressing CD38 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STI-1492 | STI 1492|STI1492 | STI-1492 are allogeneic T-cells engineered to knockout TCR alpha and express a dimeric antigen receptor targeting CD38 and containing 4-1BB and CD3-zeta signaling domains, which potentially induce toxicity against tumor cells expressing CD38 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05007418 | Phase I | STI-1492 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |